Changes to Mexican Patent Law May Impact Life Science Patent Prosecution
Jason J. Jardine & Bailey R. Arenberg
While recent amendments to Mexico’s patent laws promote faster prosecution and earlier decisions on patents, concerns abound as to the feasibility and integrity of the prosecution process.
When “About” Becomes Indefinite: Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v. Safe Foods
Jason J. Jardine & Kenneth O. Aruda, Ph.D.
The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance, “about” may render the claims indefinite. Applicants may consider: (i) expressly defining “about” in the specification; and (ii) including precise numerical ranges in dependent claims to provide clearer fallback positions.
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient With “A Unit Dosage” in Wyeth LLC v. Astrazeneca Pharmaceuticals LP.
Eric Furman, Ph.D. & Ashley C. Morales
Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal growth factor receptor inhibitor because the patent specification fails to enable treatment via the unit dosage.
PODCAST: The Biggest Patent Cases of 2026 So Far: ANDA Litigation at the Supreme Court
Jeremiah S. Helm, Ph.D. & Carol Pitzel Cruz
In this episode of IP+ with Knobbe Martens, Jeremiah Helm, Co-Chair of Knobbe Martens’ Appellate Litigation practice, and Carol Pitzel Cruz, Co-Chair of the firm’s Hatch-Waxman Litigation practice, discuss one of the most consequential IP cases so far this year: the recent SCOTUS ruling in Hikma v. Amarin. In their discussion, Jeremiah and Carol break down the main issues at play in the ANDA litigation case, including generic drug manufacturers’ use of skinny labels, the nuances of induced infringement, and why the decision may reverberate beyond the pharmaceutical industry.
Subscribe for News and Updates